SCHEMBL1960482

SCHEMBL1960482

O=CC(Br)c1ccnc(Cl)n1

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
RPS6KA5 O75582 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651852 0.78 POLB (0.41)
SCHEMBL17079438 0.78 KDM4C (0.33)
SCHEMBL15645770 0.74 MALT1 (0.37)
SCHEMBL4660326 0.74 MAPK9 (0.39) MAPK9MAPK10
SCHEMBL20746229 0.72 ALDH1A1 (0.40)
SCHEMBL10351096 0.72 L3MBTL1 (0.40)
SCHEMBL26664553 0.72 L3MBTL1 (0.40)
SCHEMBL1854514 0.70 KMO (0.30)
SCHEMBL21495102 0.70 UHRF1 (0.42)
SCHEMBL1555509 0.70 TRPV1 (0.34) MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4363416-A1 MK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-05-08 EP disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 WO disclosed
WO-2014062938-A1 RORY MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-24 WO disclosed
EP-2686317-A2 RAF KINASE INHIBITORS Selexagen Therapeutics, Inc. (US) 2014-01-22 EP disclosed
EP-2513111-A1 MK2 INHIBITORS MSD Oss B.V. (NL) 2012-10-24 EP disclosed
WO-2012125981-A2 RAF KINASE INHIBITORS SELEXAGEN THERAPEUTICS, INC. (US) 2012-09-20 WO disclosed
WO-2011073119-A1 MK2 INHIBITORS N.V. ORGANON (NL) 2011-06-23 WO disclosed